Lilly strong now, but future uncertain
Earlier this week, Bernstein Research analyst Dr. Tim Anderson said in a letter that Eli Lilly was among three Big Pharma companies facing the biggest patent losses over the next few years. Between 2011 and 2014, drugs like Zyprexa, Cymbalta, Gemzar and Evista will all go off-patent. When Lilly released its annual report this morning, the company projected 2010 earnings per share of
